Table 1.

Baseline characteristics of 282 pancreatic ductal adenocarcinoma patients who underwent R0 resection, n (%)

Characteristic	Patients, n = 282
Age in yr	61 (31-81)
> 60	136 (48.2)
≤ 60	146 (51.8)
Sex
Male	151 (53.5)
Female	131 (46.5)
Clinical symptoms
Absent	57 (20.2)
Present	225 (79.8)
Diabetes
Absent	201 (71.3)
Present	81 (28.7)
Smoking status
Absent	215 (76.2)
Present	67 (23.8)
Alcohol consumption
Absent	235 (83.3)
Present	47 (16.7)
Family history of cancer
Absent	271 (96.1)
Present	11 (3.9)
Blood type
A	87 (30.9)
B	93 (33.0)
AB	22 (7.8)
O	80 (28.4)
Tumor location
Head and neck	130 (46.1)
Body and tail	152 (53.9)
Approaches of open surgery
Pancreaticoduodenectomy	130 (46.1)
Distal pancreatectomy with splenectomy	152 (53.9)
Degree of differentiation
Well	34 (12.1)
Moderately	217 (77.0)
Poorly	31 (11.0)
Lymphovascular invasion
Absent	203 (72.0)
Present	79 (28.0)
Perineural invasion
Absent	70 (24.8)
Present	212 (75.2)
Capsular invasion
Absent	49 (17.4)
Present	233 (82.6)
Maximum tumor diameter in cm
> 4	88 (31.2)
≤ 4	194 (68.8)
T stage
T1	34 (12.1)
T2	159 (56.4)
T3	89 (31.6)
Number of metastatic lymph nodes
Absent	161 (57.1)
Present	121 (42.9)
N stage
N0	161 (57.1)
N1	92 (32.6)
N2	29 (10.3)
TNM stage
IA	20 (7.1)
IB	92 (32.6)
IIA	49 (17.4)
IIB	92 (32.6)
III	29 (10.3)
Adjuvant therapy
Absent	124 (44.0)
Present	158 (56.0)
Preoperative CA19-9 level in U/mL	172.4 (0.6-55412.0)
> 336.4	77 (27.3)
≤ 336.4	205 (72.7)
Preoperative plasma fibrinogen concentration in g/L	3.02 (1.20-6.70)
> 3.31	141 (50.0)
≤ 3.31	141 (50.0)
Preoperative plasma albumin level in g/L	42.6 (23.2-54.0)
> 45.2	85 (30.1)
≤ 45.2	197 (69.9)
Preoperative FAR	0.07 (0.03-0.21)
> 0.08	126 (44.7)
≤ 0.08	156 (55.3)

FAR: Fibrinogen-to-albumin ratio; TNM: Tumor-Node-Metastasis.